ALISO VIEJO, Calif. – July 31, 2023 – MicroVention, Inc. today announced new 5-year clinical trial data along with size additions for its WEB™ Aneurysm Embolization System, reinforcing WEB's position as the most well-studied intrasaccular device available today.
The 5-year data demonstrate durable, long-term aneurysm occlusion outcomes and continued favorable safety results, adding to the extensive body of clinical evidence supporting the WEB System across a broad range of aneurysm types and sizes.
Alongside the new data, MicroVention announced additional size options for the WEB System, expanding the range of aneurysm anatomies that can be treated with this intrasaccular flow disruption technology.
"With over a decade of clinical use and now five years of long-term data, WEB continues to demonstrate durable outcomes for patients with complex aneurysms," said a MicroVention representative. "These new size additions further expand our ability to treat a broader range of patients."
About MicroVention
MicroVention, Inc. is committed to advancing the treatment of complex diseases within the neurovascular market by providing innovative technologies and evidence-driven education for physicians dedicated to improving patient care. As a wholly owned subsidiary of Terumo Corporation, MicroVention develops, manufactures and markets innovative neuro-interventional products and services for the diagnosis and treatment of neurovascular diseases and adjacent markets.
